Sanofi Bangladesh Limited’s majority stake is acquired by Beximco Pharma, Bangladesh
Beximco Pharmaceuticals Limited, one of leading pharmaceutical company based at Bangladesh, have completed its acquisition of the majority stake (54.6%) in Sanofi... Read More
Sanofi received additional indication approval for Plavix
European Commission (EC) has approved an additional indication for Plavix (clopidogrel) to include its use in combination with aspirin in adult patients... Read More
Sanofi-kymab-deal: Sanofi’s acquisition of a clinical-stage biopharmaceutical company Kymab
Global pharmaceutical company, Sanofi will acquire a clinical-stage biopahrmaceutical company Kymab. Sanofi will acquire Kymab for an upfront payment of approximately $1.1... Read More
Sanofi and Merck to conduct phase 2 trial of THOR-707 in combo with Keytruda
Sanofi has entered into an agreement with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the US and Canada)... Read More
Regeneron, Sanofi initiates clinical trial in Kevzara to treat COVID-19
Regeneron Pharmaceuticals and Sanofi have started a clinical programme evaluating Kevzara (sarilumab) in patients hospitalized with severe coronavirus (COVID-19) infection. Kevzara is... Read More
Case Study: USFDA approval of AbbVie’s RINVOQ (upadacitinib)
U.S. Food and Drug Administration (FDA) has approved RINVOQ™ (upadacitinib), a 15 mg, once-daily oral Janus kinase (JAK) inhibitor, for the treatment... Read More
Case Study: EC’s conditional marketing approval to Libtayo for advanced CSCC
Posted on02 Jul 2019
Tagscemiplimab, Conditional marketing authorisation, EU marketing authorization, Libtayo, MAB, Regeneron, Sanofi
Comments0
The European Commission (EC) has granted conditional marketing authorization for Libtayo (cemiplimab) for the treatment of adults with metastatic or locally advanced... Read More
Top 10 Global Pharmaceutical Company in 2018
Posted on26 May 2019
Comments0
US FDA approval of 0.5 ml dose of Sanofi’s Fluzone Quadrivalent in children as young as 6 months of age
The US Food and Drug Administration (FDA) has approved the use of the 0.5 mL dose of Fluzone Quadrivalent (influenza vaccine) to... Read More
2018 Pharma Deal: Sanofi’s agreement to buy Bioverati @ $10.9 billion
Posted on18 Dec 2018
TagsBioverati, global pharma deals, global pharma licensing deal, pharma acquisition, pharma deal, Sanofi
Comments0
Sanofi and Bioverativ Inc., a biopharmaceutical company focused on therapies for hemophilia and other rare blood disorders, have entered into a definitive... Read More